The breakthrough could spare thousands of patients unnecessary therapy while allowing others to receive more intensive care sooner.

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

For her new book, journalist Carter Sherman interviewed over 100 young people about why they’re not having sex. She says they ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

Imagion Biosystems (ASX: IBX) has announced it will fast-track a new batch of MagSense HER2 imaging agent ahead of a Phase 2 ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...